BiondVax Pharmaceuticals Signs Collaborative Agreement for Development of NanoAbs
Mar 24, 2022 By MarketDepth
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) today announced that it has signed a definitive agreement with Max Planck Society and the University Medical Center Göttingen (UMG) to enter into a strategic collaboration for the development of innovative nanosized antibodies.
“The NanoAb platform is an incredible opportunity for BiondVax. It will serve as a basis for an exciting new pipeline of commercially attractive products to address large and growing markets significantly underserved by existing biological treatments,”
Mr. Amir Reichman, BiondVax’s CEO
BiondVax is now planning a rapid development path to mass-produce NanoAbs through recombinant protein manufacturing in sites such as BiondVax’s GMP biologics manufacturing facility in Jerusalem. Development of NanoAbs has already begun, and initial preclinical results are expected in 2023.
“I am pleased that with BiondVax we have succeeded not only in finding a licensee but also a cooperation partner for the promising technology of nano-antibodies. Dirk Görlich and his team at the Max Planck Institute for Multidisciplinary Sciences, together with the University Medical Center Göttingen, have developed an innovative therapeutic approach within less than two years, which could also be used against COVID-19, among other things.”
Prof. Dr. Martin Stratmann, President of the Max Planck Society
BiondVax will retain an exclusive option for an exclusive worldwide license at pre-agreed commercial terms for further development and commercialization of each generated NanoAb.
